Lipiodol, an oil-based radio-opaque contrast agent, is indicated for hysterosalpingography in adults, lymphography in adult and pediatric patients, and selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC).
To eliminate the risk of breakage and cracking issues, the new Lipiodol will be supplied in glass vials, rather than glass ampules.
“Guerbet has spent the last 10 years investing in best practices and procedures to ensure the availability of Lipiodol to all US patients,” said Massimo Carrara, Guerbet Vice President for North America. “The new FDA registered manufacturing site, along with our new packaging, ensures critical availability of the product in a preferred vial format.”
Customers should expect delivery of the newly manufactured product sometime this week.
For more information call (877) 729-6679 or visit Guerbet.com.